Ketamine Therapy for Depression: Clinical Evidence and Patient Outcomes in 2024

For people with depression that has not responded to standard antidepressants, ketamine therapy represents one of the most significant clinical developments in psychiatry in decades. Where traditional antidepressants take weeks to produce relief and fail to help a substantial proportion of patients, ketamine infusion therapy can produce measurable antidepressant effects within hours — including in people who have tried multiple medications without adequate response. This blog covers what ketamine therapy for depression actually involves, what the clinical evidence shows, and how it compares to other treatment options for people exploring alternatives to standard antidepressant care.

Treatment-Resistant Depression and Why Standard Medications Fail

Treatment-resistant depression (TRD) is typically defined as depression that has not responded adequately to at least two different antidepressant trials at therapeutic doses and adequate duration. Approximately 30 percent of people with major depressive disorder meet this threshold — a substantial population for whom standard first-line treatment has proven insufficient. The reasons standard medications fail are not fully understood, but contributing factors include:

• Genetic variations in how medications are metabolized — some people are poor or ultra-rapid metabolizers of specific antidepressants
• Neuroinflammatory mechanisms that do not respond to monoamine-targeted medication
• Underlying conditions — including bipolar spectrum disorder, PTSD, or personality disorders — that alter medication response
• Inadequate dosing or duration in prior trials — medication that appears to have failed may not have been given an adequate chance
• Comorbid substance use that undermines medication effectiveness

The Mechanism Behind Ketamine Infusion Therapy

Ketamine infusion therapy is administered intravenously in a clinical setting, typically over 40 to 60 minutes per session. The standard initial protocol involves six infusions over two to three weeks, followed by maintenance infusions as needed depending on response duration. The controlled clinical environment allows real-time monitoring of vital signs and the ability to manage dissociative side effects as they occur. IV infusion provides the most precise dosing and the most reliable absorption, making it the delivery method with the most clinical data supporting its use.

Neurobiological Changes at the Synaptic Level

Ketamine’s antidepressant mechanism operates through a cascade of neurobiological events that differ fundamentally from monoamine-based treatments. At the synaptic level, ketamine blocks NMDA glutamate receptors, which triggers a downstream surge in AMPA receptor activity and stimulates the release of brain-derived neurotrophic factor (BDNF). BDNF is a key driver of synaptic plasticity — the brain’s ability to form and strengthen neural connections. In depression, synaptic density in the prefrontal cortex and hippocampus is reduced.

Clinical Outcomes From Recent Ketamine Clinic Studies

The clinical evidence base for ketamine infusion therapy for depression has grown substantially over the past decade. Randomized controlled trials consistently demonstrate response rates of 50 to 70 percent in TRD populations — significantly higher than the response rates seen with next-step traditional antidepressant options in the same population. 

The speed of response is also clinically significant, with many patients reporting noticeable improvement within 24 hours of the first infusion and meaningful antidepressant effects emerging within the first week of the initial infusion series.

Response Rates in Patients With Severe Depression

Key findings from recent clinical literature include:

• 50 to 70 percent of TRD patients respond to an initial ketamine infusion series, compared to 10 to 20 percent response rates with next-step antidepressant trials in the same population
• Remission rates — complete resolution of depressive symptoms — are lower than response rates but still clinically meaningful at approximately 20 to 35 percent after an initial series
• Response is typically defined as a 50 percent or greater reduction in depressive symptom scores, with many patients achieving this threshold after one to three infusions
• Patients with suicidal ideation show particularly rapid reduction in suicidal thinking—sometimes within hours  is one of the most clinically significant findings in the ketamine literature

Duration of Relief and Long-Term Management Strategies

The primary limitation of ketamine therapy is that its effects are not permanent. In most people, the antidepressant effect of an initial infusion series lasts between two weeks and three months, with significant individual variation. Long-term management strategies that extend the duration of ketamine’s benefit include:

• Maintenance infusions
• Integration with psychotherapy
• Combination with oral antidepressants
• Lifestyle factors

Dissociative Therapy and Patient Safety Protocols

Ketamine produces dissociative effects at infusion doses—perceptual alterations, a sense of detachment from the body, and changes in the experience of time and space. These effects are dose-dependent, predictable, and temporary, typically resolving within an hour of infusion completion. Comprehensive patient safety protocols for ketamine infusion include:

• Pre-treatment medical and psychiatric screening—ruling out contraindications including active psychosis, uncontrolled hypertension, and significant substance use disorder
• Continuous vital sign monitoring throughout the infusion
• Clinical staff present throughout the session to manage dissociative effects and provide reassurance
• Post-infusion recovery period before discharge — typically 30 to 60 minutes
• Transportation requirement — patients are not permitted to drive on the day of infusion
• Psychological support during and after sessions for patients who find the dissociative experience distressing

Comparing Ketamine to Other Antidepressant Alternatives

Ketamine is one of several emerging treatments for treatment-resistant and severe depression. Understanding how it compares to other available options helps clinicians and patients make informed treatment decisions. The table below outlines the key comparison points:

Mental Health Therapy Integration at Shine Mental Health

Ketamine therapy produces its best and most durable outcomes when it is integrated into a comprehensive mental health treatment plan rather than administered in isolation.

Shine Mental Health provides ketamine infusion therapy within a clinically integrated framework that includes psychiatric evaluation, ongoing medication management, and psychotherapy coordination to maximize and extend the benefits of each treatment.

Contact Shine Mental Health today to speak with a psychiatric specialist and find out whether ketamine therapy for depression is the right next step in your treatment.

FAQs

1. How quickly does ketamine infusion therapy produce relief compared to traditional antidepressants?

Ketamine infusion therapy typically produces noticeable antidepressant effects within 24 hours of the first infusion and a meaningful clinical response within the first week of an initial six-infusion series—compared to the four to six week minimum timeline for SSRIs and SNRIs and the eight to twelve week timeline for a full therapeutic response. This speed of action is particularly significant for patients with severe depression or active suicidal ideation, where waiting weeks for a medication to work carries meaningful clinical risk.

2. Can ketamine clinic treatment work when SSRIs and SNRIs have already failed?

Yes — and this is precisely the population for which ketamine has the most compelling evidence. Because ketamine acts on the glutamate system rather than the monoamine system targeted by SSRIs and SNRIs, prior non-response to those medications does not predict non-response to ketamine. Clinical trials in treatment-resistant populations—defined by failure of two or more adequate antidepressant trials—consistently show 50 to 70 percent response rates to ketamine infusion therapy.

3. What happens to your brain during dissociative therapy sessions at a ketamine clinic?

During a ketamine infusion session, the medication blocks NMDA glutamate receptors, triggering a cascade that includes a surge in AMPA receptor activity, release of BDNF, and rapid increases in synaptic density in the prefrontal cortex and hippocampus—the brain regions most affected by depression. The dissociative effects—perceptual alterations and sense of detachment—reflect the glutamate system disruption and typically resolve within an hour of infusion completion, while the neuroplastic changes that produce antidepressant effects persist and continue to develop over the following days.

4. How long do the benefits of rapid-relief depression treatment typically last?

The antidepressant effects of a ketamine infusion series typically last between two weeks and three months, with significant individual variation—some patients maintain response for six months or longer, while others notice return of symptoms within two to four weeks. Maintenance infusions on a scheduled or as-needed basis, combined with psychotherapy during the period of enhanced neuroplasticity and optimization of concurrent antidepressant medication, are the primary strategies for extending the duration of benefit.

5. Is ketamine a permanent solution or does it require ongoing mental health therapy integration?

Ketamine is not a permanent cure for depression — it is a powerful catalyst for neuroplastic change that creates a window of enhanced treatment responsiveness. For most people, it requires ongoing management through maintenance infusions, psychotherapy that takes advantage of the enhanced neuroplasticity window, and concurrent optimization of oral psychiatric medication. Integrated with comprehensive mental health treatment, ketamine can shift the course of treatment-resistant depression significantly — but it works best as part of a plan rather than as a standalone intervention.